Virtus ETF Advisers LLC Humanigen, Inc Transaction History

Virtus ETF Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $64,366 - $121,784	-36,572 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $3,924 - $8,606	-2,168 Reduced 5.6%	36,572 $110,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $103,889 - $233,324	28,385 Added 274.12%	38,740 $144,000
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $3,237 - $9,735	-546 Reduced 5.01%	10,355 $61,000
Q2 2021 Aug 10, 2021	SELL	$13.54 - $22.74 $192,335 - $323,021	-14,205 Reduced 56.58%	10,901 $189,000
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $5,667 - $10,461	439 Added 1.78%	25,106 $480,000
Q4 2020 Feb 12, 2021	BUY	$7.97 - $21.66 $196,595 - $534,287	24,667 New	24,667 $432,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.